Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19 – New England Journal of Medicine Commentary on Twitter AZD7442 (tixagevimab/cilgavimab) found to have about 76% efficacy in preventing symptomatic Covid-19 infection. https://t.co/8tmvz3xI4I pic.twitter.com/fOegZjBRA6 — NEJM (@NEJM) April 20, 2022
The post RCT: Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for prevention of Covid-19. appeared first on Links Medicus.
Assurez-vous d'entrer toutes les informations requises, indiquées par un astérisque (*). Le code HTML n'est pas autorisé.